REVIEW PAPER
The newest and classic biomarkers of sepsis in HIV-infected adult patients
1
Department of Infectious and Tropical Diseases and Hepatology, Medical University of Warsaw, Hospital for Infectious Diseases, Poland
Submission date: 2021-01-26
Acceptance date: 2021-03-24
Publication date: 2021-12-26
HIV & AIDS Review 2021;20(4):257-263
KEYWORDS
TOPICS
ABSTRACT
Sepsis is one of the major causes of mortality of patients worldwide, and patients with human immuno deficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS) are at higher risk of developing it. Given the importance of quick diagnosis, the demand for sepsis biomarkers is high. In this article, the authors reviewed the available sepsis biomarkers, and assessed whether the biomarkers were analyzed in patients with HIV/AIDS.
We investigated the available literature on classic inflammatory biomarkers, such as procalcitonin (PCT) and interleukin-6 (IL-6) as well as new biomarkers of sepsis, including soluble form of urokinase-
type plasminogen activator receptor (suPAR), proadrenomedullin (proADM), soluble triggering receptor expressed on myeloid cells 1 (sTREM-1), growth arrest-specific 6 (Gas6), and microRNA (miRNA)
in immunocompetent patients and patients living with HIV/AIDS. Various biomarkers have a diagnostic value (PCT, sTREM-1), others present a prognostic value (suPAR, Gas6, PSP, HBP), and some biomarkers have both values (IL-6, proADM, sCD14-ST, miRNA). Combining at least two different biomarkers has the best potential to bring high sensitivity and specificity of diagnosis.
To our knowledge, many of discussed novel inflammatory biomarkers, such as presepsin, pancreatic stone protein/regenerating protein (PSP/reg), or heparin-binding protein (HBP), were not yet studied in a population of patients with HIV/AIDS and sepsis.
So far, there is not a one biomarker used as a golden standard in diagnosis of sepsis. Monitoring at least two biomarkers might increase the chance of early detection of sepsis. Further research is needed to find biomarkers diagnosing sepsis in patients with AIDS.
We investigated the available literature on classic inflammatory biomarkers, such as procalcitonin (PCT) and interleukin-6 (IL-6) as well as new biomarkers of sepsis, including soluble form of urokinase-
type plasminogen activator receptor (suPAR), proadrenomedullin (proADM), soluble triggering receptor expressed on myeloid cells 1 (sTREM-1), growth arrest-specific 6 (Gas6), and microRNA (miRNA)
in immunocompetent patients and patients living with HIV/AIDS. Various biomarkers have a diagnostic value (PCT, sTREM-1), others present a prognostic value (suPAR, Gas6, PSP, HBP), and some biomarkers have both values (IL-6, proADM, sCD14-ST, miRNA). Combining at least two different biomarkers has the best potential to bring high sensitivity and specificity of diagnosis.
To our knowledge, many of discussed novel inflammatory biomarkers, such as presepsin, pancreatic stone protein/regenerating protein (PSP/reg), or heparin-binding protein (HBP), were not yet studied in a population of patients with HIV/AIDS and sepsis.
So far, there is not a one biomarker used as a golden standard in diagnosis of sepsis. Monitoring at least two biomarkers might increase the chance of early detection of sepsis. Further research is needed to find biomarkers diagnosing sepsis in patients with AIDS.
REFERENCES (63)
1.
Singer M, Deutschman CS, Seymour CW, et al. The third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA 2016; 315: 801-810.
2.
Morrow KN, Coopersmith CM, Ford ML. IL-17, IL-27 and IL-33: a novel axis linked to immunological dysfunction during sepsis. Front Immunol 2019; 10: 1982.
3.
Angus DC. The lingering consequences of sepsis: a hidden public health disaster? JAMA 2010; 304: 1833-1834.
4.
Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 2001; 69: 89-95.
6.
Chirouze C, Schuhmacher H. Low serum PCT level accurately predicts the absence of bacteriemia in adult patients with acute fever. Clin Inf Dis 2002; 35: 156-161.
7.
Jones AE, Fiechtl JF, Brown MD, et al. Procalcitonin test in the diagnosis of bacteremia: a meta-analysis. Ann Emerg Med 2007; 50: 34-41.
8.
Dolin HH, Papadimos TJ, Stepkowski S, et al. A novel comibination of biomarkes to herald the onset of sepsis prior to the manifestation of symptoms. Shock 2018; 49: 364-370.
9.
Zhang T, Wang Y, Yang Q, et al. Procalcitonin-guided antibiotic therapy in critically ill adults: a meta-analysis. BMC Infect Dis 2017; 17: 514.
10.
Jensen JU, Heslet L, Jensen TH, et al. Procalcitonin increase in early identification of critically ill patients at high risk of mortality. Crit Care Med 2006; 34: 2596-2602.
11.
Bele N, Darmon M, Coquet I, et al. Diagnostic accuracy of procalcitonin in critically ill immunocompromised patients. BMC Infect Dis 2011; 11: 224.
12.
Kang YA, Kwon SY, Yoon HI, et al. Role of C-reactive protein and procalcitonin in differentiation of tuberculosis from bacterial community acquired pneumonia. Korean J Intern Med 2009; 24: 337-342.
13.
Schleicher GK, Herbert V, Brink A, et al. Procalcitonin and C-reactve protein level in HIV-positive subjects with tuberculosis and pneumonia. Eur Respir J 2005; 25: 688-692.
14.
Nyamande K, Lalloo UG. Serum procalcitonin distinguishes CAP due to bacteria, Mycobacterium tuberculosis and PJP. Int J Tuberc Lung Dis 2006; 10: 510-515.
15.
Janssen S, Schutz C, Ward A, et al. Mortality in severe human immunodeficiency virus-tuberculosis associates with innate immune activation and dysfunction of monocytes. Clin Infect Dis 2017; 65: 73-82.
16.
Bokun LV, Huang J, Yuan H, et al. Tumor necrosis factor-α as a diagnostic marker for neonatal sepsis: a meta-analysis. Sci World J 2014; 2014: 471463.
17.
Wolf J, Rose-John S, Garbers C. Interleukin-6 and its receptors: a highly regulated and dynamic system. Cytokine 2014; 70: 11-20.
18.
Wong HR, Cvijanovich NZ, Hall M, et al. Interleukin-27 is a novel candidate diagnostic biomarker for bacterial infection in critically ill children. Crit Care 2012; 16: R213.
19.
Wong HR. Performance of IL-27 as a sepsis diagnostic biomarker in the critically ill adults. J Crit Care 2014; 29: 718-722.
20.
Amancio RT, Japiassu AM, Gomes RN, et al. The innate immune response in HIV/AIDS septic shock patients: a comparative study. PLoS One 2013; 8: e68730.
21.
Taniguchi T, Koido Y, Aiboshi J, et al. Change in the ratio of interleukin-6 to interleukin-10 predicts a poor outcome in patients with systemic inflammatory response syndrome. Crit Care Med 1999; 27: 1262-1264.
22.
Sun J, Su J, Xie Y, et al. Plasma IL-6/IL-10 ratio and IL-8, LDH, and HBDH level predict the severity and the risk of death in AIDS patients with pneumocystis pneumonia. J Immunol Res 2016; 2016: 1583951.
23.
Sandquist M, Wong HR. Biomarkers of sepsis and their potential value in diagnosis, prognosis and treatment. Exp Rev Clin Immunol 2014; 10: 1349-1356.
24.
Ni W, Han Y, Zhao J, et al. Serum soluble urokinase-type plasminogen activator receptor as a biological marker of bacterial infection in adults: a systematic review and meta-analysis. Sci Rep 2016; 6: 39481.
25.
Suberviola B, Castellanos-Ortega A, Ruiz Ruiz A, et al. Hospital mortality prognostication in sepsis using the new biomarkers suPAR and proADM in a single determination on ICU admission. Intensive Care Med 2013; 39: 1945-1952.
26.
Henriquez-Camacho C, Losa J. Biomarkers for sepsis. Biomed Res Int 2014; 2014: 547818.
27.
Sidenius N, Sier CF, Ullum H, et al. Serum level of soluble urokinase-type plasminogen activator receptor is a strong and independent predictor of survival in human immunodeficiency virus infection. Blood 2000; 96: 4091-4095.
28.
Kirkegaard-Klitbo DM, Langkilde A, Mejer N, et al. Soluble urokinase plasminogen activator receptor is a predictor of incident non-AIDS comorbidity and all-cause mortality in human immunodeficiency virus type 1 infection. J Infect Dis 2017; 216: 819-823.
29.
Rasmussen LJ, Knudsen A, Katzenstein TL, et al. Soluble urokinase plasminogen activator receptor (suPAR) is a novel, independent predictive marker of myocardial infarction in HIV-1-infected patients: a nested case-control study. HIV Med 2016; 17: 350-357.
30.
Akpinar S, Rollas K, Alagoz A, et al. Performance evaluation of MR-proadrenomedullin and other scoring systems in severe sepsis with pneumonia. J Thorac Dis 2014; 6: 921-929.
31.
Spoto S, Cella E, de Cesaris M, et al. Procalcitonin and Mr-proadrenomedullin combination with SOFA and qSOFA scores for sepsis diagnosis and prognosis: a diagnostic algorithm. Shock 2018; 50: 44-52.
32.
Angeletti A, Battistoni F, Fioravanti M, et al. Procalcitonin and midregional pro-adrenomedullin test combination in sepsis diagnosis. Clin Chem Lab Med 2013; 5: 1059-1067.
33.
Albrich WC, Madhi SA, Adrian PV, et al. Pneumococcal colonisation density: a new marker for disease severity in HIV-infected adults with pneumonia. BMJ Open 2014; 4: e005953.
34.
Bouchon A, Dietrich J, Colonna M. Cutting edge: inflammatory responses can be triggered by TREM-1, a novel receptor expressed on neutrophils and monocytes. J Immunol 2000; 164: 4991-4995.
35.
Gibot S, Cravoisy A, Levy B, et al. Soluble triggering receptor expressed on myeloid cells and the diagnosis of pneumonia. N Engl J Med 2004; 350: 451-458.
36.
Su L, Xie L, Liu D. Urine sTREM-1 may be a valuable biomarker in diagnosis and prognosis of sepsis-associated acute kidney injury. Crit Care 2015; 19: 281.
37.
Wu Y, Wang F, Fan X, et al. Accuracy of plasma sTREM-1 for sepsis diagnosis in systemic inflammatory patients: a systematic review and meta-analysis. Crit Care 2012; 16: R229.
38.
Aksaray S, Alagoz P, Inan A, et al. Diagnostic value of sTREM-1 and procalcitonin levels in the early diagnosis of sepsis. North Clin Istanb 2017; 3: 175-182.
39.
Hyun J, McMahon RS, Lang AL, et al. HIV and HCV augments inflammatory responses through increased TREM-1 expression and signaling in Kupffer and Myeloid cells. PLoS Pathog 2019; 15: e1007883.
40.
Hsiao FC, Lin YF, Hsieh PS, et al. Circulating growth arrest-specific 6 protein is associated with adiposity, systemic inflammation, and insulin resistance among overweight and obese adolescents. J Clin Endocrinol Metab 2013; 98: 267-274.
41.
Borgel D, Clauser S, Bornstain C, et al. Elevated growth-arrest-specific protein 6 plasma levels in patients with severe sepsis. Crit Care Med 2006; 34: 219-222.
42.
Stalder G, Que YA, Calzavarini S, et al. Study of early elevated Gas6 plasma level as a predictot of mortality in a prospective cohort of patients with sepsis. PLoS One 2016; 11: e0163542.
43.
Chua BA, Ngo JA, Situ K, Morizono K. Roles of phosphatidylserine exposed on the viral envelope and cell membrane in HIV-1 replication. Cell Commun Signal 2019; 17: 132.
44.
Benz F, Roy S, Trautwein C, Roderburg C, Luedde T. Circulating microRNAs as biomarkers for sepsis. Int J Mol Sci 2016; 17: 78.
45.
Zhang W, Jia J, Liu Z, Si D, Ma L, Zhang G. Circulating microRNAs as biomarkers for sepsis secondary to pneumonia diagnosed via sepsis 3.0. BMC Pulm Med 2019; 19: 93.
46.
Balasubramaniam M, Pandhare J, Dash C. Are microRNAs important players in HIV-1 infection? An update. Viruses 2018; 10: 110.
47.
Jin C, Cheng L, Hoxtermann S, et al. MicroRNA-155 Is a Biomarker of T-cell Activation and Immune Dysfunction in HIV-1-infected Patients. HIV Med 2017; 18: 354-362. .
48.
Mussap M, Noto A, Fravega M, Fanos V. Soluble CD14 subtype presepsin (sCD14-ST) and lipopolysaccharide binding protein (LBP) in neonatal sepsis: new clinical and analytical perspectives for two old biomarkers. J Matern Fetal Neonatal Med 2011; 24: 12-14.
49.
Wu J, Hu L, Zhang G, Wu F, He T. Accuracy of presepsin in sepsis diagnosis: a systematic review and meta-analysis. PLoS One 2015; 10: e0133057.
50.
Tong X, Cao Y, Yu M, Han C. Presepsin as a diagnostic marker for sepsis: evidence from a bivariate meta-analysis. Ther Clin Risk.
52.
Wu Q, Nie Y, Wu FX, Zou XL, Chen FY. Prognostic value of high-sensitivity c-reactive protein, procalcitonin and pancreatic stone protein in pediatric sepsis. Med Sci Monit 2017; 23: 1533-1539.
53.
Linder A, Arnold R, Boyd JH, et al. Heparin-binding protein measurement improves the prediction of severe infection with organ dysfunction in the emergency department. Crit Care Med 2015; 43: 2378-2386.
54.
Chen S, Zhang C, Hong G, et al. Meta-analysis of the diagnostic efficacy of heparin binding protein in adult sepsis. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue 2019; 31: 1330-1334.
55.
Holub M, Dzupova O, Ruzkova M, et al. Selected biomarkers correlate with the origin and severity of sepsis. Mediators Inflamm 2018; 2018: 7028267.
56.
Silva JM Jr, De Sousa dos Santos S. Sepsis in AIDS patients: clinical, etiological and inflammatory characteristics. J Int AIDS Soc 2013; 16: 17344.
57.
Vidal-Cortés P, Lameiro-Flores P, Mourelo-Fariña M, et al. Sepsis in HIV patients admitted to the ICU. Critical Care 2013; 17: P513.
58.
Mrus JM, Braun LA, Yi MS, Linde-Zwirble WT, Johnston JA. Impact of HIV/AIDS on care and outcomes of severe sepsis. Critical Care 2005; 9: R623-R630.
59.
Cribbs S. Characteristics and outcomes of HIV-infected patients with severe sepsis: continued risk in the post-highly active antiretroviral therapy era. Crit Care Med 2015; 43: 1638-1645.
60.
Wiewel MA, Huson MA, van Vught LA, et al. Impact of HIV infection on the presentation, outcome and host response in patients admitted to the intensive care unit with sepsis, a case control study. Crit Care 2016; 20: 322.
61.
ECDC, Infographic: HIV late diagnosis – 2018 data. Available at: https://www.ecdc.europa.eu/en/....
62.
Yoon C, Chaisson LH, Patel SM, et al. Diagnostic accuracy of C-reactive protein for active pulmonary tuberculosis: a meta-analysis. Int J Tuberc Lung Dis 2017; 21: 1013-1019.
63.
Bedell RA, van Lettow M, Meaney C, et al. Predictive value of C-reactive protein for tuberculosis, bloodstream infection or death among HIV-infected individuals with chronic, non-specific symptoms and negative sputum smear microscopy. Trop Med Int Health 2018; 23: 254-262.
Share
RELATED ARTICLE
| eISSN: | 1732-2707 |
| ISSN: | 1730-1270 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
